A phase II study of abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, met its primary endpoint of reducing expression of Ki67, a biomarker of cell proliferation, after two weeks of treatment.
Excess weight is linked to an especially high risk of developing breast cancer in postmenopausal women with cardiovascular disease, according to research from the International Agency for Research on Cancer. The study was published in Cancer.
